Replies to post #21658 on Nutra Pharma Corp (NPHC)

[maverick81]

Exactly...


300 mil market cap would put us at .20
Even a quarter of that is .05

From here thats over 5000%

That's conservative REAl potential based on fundamentals.

Strong buy and hold here.


Mav

[spss1]

once they secure funding for phase 2 trials, then game on. I am sure they must be very close to securing that.

Add whatever you can and will have happy holidays soon.

[Millenium323]

It's becoming obvious the CEO here doesn't know how to get a proper valuation for his stock. How does a pharmaceutical company with a product with an orphan drug designation have a sub $2 million market cap? It should be a minimum of 20x higher than that. That is on the CEO and as a result he is unnecessarily blowing out the share structure.

[fly_fisherman]

Excellent observation....

Well, let's see... OWC* ran to over $300M market cap on possible orphan drug status with no clinical trials, product, or revs at the time. We already have a celebrity endorsement on one of our existing products and awaiting Phase II study news, so....

Cache....

300 Million and not near the potential here.

We sit at 1.3 million market cap now. Laughable. Not for long!!!

Its all in the market cap folks!!!

Just for Grins 300 million would represent a PPS of .16 cents for NPHC.

Our Orphan Drug Status is for a drug addressing multiple key diseases:

FDA TRIALS PHASE II Soon!!!

http://www.receptopharm.com/drug_development/

RPI-78M is being developed for the treatment of Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). Other neurological disorders that may be served by RPI-78M include Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS).


We are NO one trick pony either. I believe the Opioid crisis has put us in the forefront of some amazing potential with another trick/solution.

Nyloxin
https://nyloxin.com/

https://www.nbcmiami.com/news/local/South-Florida-Company-Turns-Cobra-Venom-Into-Healing-Treatment-413791863.html


“All the principle work has been in humans. So, the Nyloxin product is amazing. It’s non-addictive, no opiate, non-narcotic. In the last model, it outperformed morphine. It lasted six hours longer than morphine without any of the side effects,” explained Rik Deitsch, CEO of Nutra Pharma Corp.

Supported by Jack Brewer. Non addictive pain solutions!!!!

Retweeted!!!!

Jack Brewer @JackBrewerBSI
Oct 2
I don’t know what I would do without my @nyloxin!! Keeps me going
Nutra Pharma @nutrapharma
Embedded
For #pain relief try @nyloxin amazing products.

For #pain relief try @nyloxin amazing products. Shop now at https://t.co/41IxnXhnBp pic.twitter.com/NCDcXo7wtn

— Nutra Pharma (@nutrapharma) October 2, 2017

Key Endorsement....

Jack Brewer is the Executive Chairman & Portfolio Manager of The Brewer Group.
Very successful investor/financier and has connections with Bio Tech!!! Visits Fox Business frequently!

We have 8 additional tricks in our pipeline along with 21 patents!

http://www.receptopharm.com/drug_development/pipeline.php

Also: Pet Pain Away now published in veterinarian textbook.
http://www.otcmarkets.com/stock/NPHC/news/New-Edition-of-Textbook-on-Treating-Canine-Arthritis-Includes-Nutra-Pharma-Pain-Remedy?id=166273&b=y

Folks selling now and not loading up are going to miss out on one HUGE BIGGLY opportunity!!!